Opendata, web and dolomites

NATURE-ETN SIGNED

Nucleic Acids for Future Gene Editing, Immunotherapy and Epigenetic Sequence Modification

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NATURE-ETN project word cloud

Explore the words cloud of the NATURE-ETN project. It provides you a very rough idea of what is the project "NATURE-ETN" about.

industry    grow    basic    workshops    skillset    culture    epigenetic    limitations    despite    disease    human    genomics    fellows    yield    deletions    cell    paradigm    manipulation    deep    immunotherapy    combination    chemists    century    expertise    mutations    crispr    stage    quality    disciplinary    laboratories    therapy    today    base    boundaries    technologies    environment    immunotherapies    meet    discoveries    dna    serious    breakthrough    commercial    career    excellence    tools    outcomes    crystallography    therapies    21st    applicability    predicted    planning    business    nas    transferable    receive    smes    cells    engineering    extend    intersectoral    therapeutic    cas9    questions    chemistry    tech    functioning    unrivalled    training    off    treatment    world    etn    biologists    editing    biomaterials    translation    undesired    sequencing    acid    nucleic    scientific    biotech    cancer    nature    outstanding    15    skills    disruptive    give    regarding    na    materials    insertions    originating    pioneering    medicine    generation    leverage    leaders    gene    prolonged    combined   

Project "NATURE-ETN" data sheet

The following table provides information about the project.

Coordinator
DUBLIN CITY UNIVERSITY 

Organization address
address: Glasnevin
city: DUBLIN
postcode: 9
website: www.dcu.ie

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 4˙041˙816 €
 EC max contribution 4˙041˙816 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2024-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DUBLIN CITY UNIVERSITY IE (DUBLIN) coordinator 824˙052.00
2    THE UNIVERSITY OF READING UK (READING) participant 606˙345.00
3    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 505˙576.00
4    USTAV ORGANICKE CHEMIE A BIOCHEMIE, AV CR, V.V.I. CZ (PRAHA 6) participant 469˙743.00
5    ATDBIO LIMITED UK (SOUTHAMPTON HAMPSHIRE) participant 303˙172.00
6    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 303˙172.00
7    ECOLE NATIONALE SUPERIEURE DE CHIMIE DE PARIS FR (PARIS CEDEX 05) participant 274˙802.00
8    NATIONAL INSTITUTE FOR BIOPROCESSING RESEARCH AND TRAINING LIMITED IE (BLACKROCK DUBLIN) participant 274˙684.00
9    BASECLICK GMBH DE (NEURIED) participant 252˙788.00
10    UNIWERSYTET WARSZAWSKI PL (WARSZAWA) participant 227˙478.00

Map

 Project objective

Nucleic acid (NAs) therapies are predicted to yield major advances in the treatment of human disease and new approaches in NA design are required to extend the boundaries of today`s gene editing technologies, cancer immunotherapies, and epigenetic base manipulation tools. Current gene editing technologies involving CRISPR-Cas9, despite their wide applicability, have serious limitations involving off-target or prolonged effects that produce mutations, insertions, and deletions leading to undesired therapeutic outcomes. Questions also remain regarding the development and delivery of NAs for manipulation of T-cells, now seen as the new paradigm in cancer research. NATURE-ETN will meet this challenge by engineering new biomaterials and therapies to extend the boundaries of i.) gene editing technology, ii.) cancer immunotherapy, and iii.) epigenetic base manipulation. Our research programme involves world-leading chemists and biologists in combination with high-tech/biotech SMEs and industry partners. We will use our combined expertise in NA chemistry, DNA crystallography, materials chemistry, cell culture, and epigenetic sequencing to develop an outstanding multi-disciplinary environment were 15 Early Stage Researchers will receive unrivalled research training in the most exciting gene therapy research today. The intersectoral training provided will encompass scientific and transferable skills, an understanding of industry, and features targeted workshops in sequencing and genomics along with quality/business management and future career planning. NATURE-ETN will leverage breakthrough discoveries—some originating from our own laboratories—to provide training excellence to give our fellows a deep skillset in the translation of basic research into high functioning commercial NA biomaterials. NATURE-ETN will develop the next generation of pioneering scientific leaders in Europe where they will grow our commercial need for disruptive technologies in 21st century medicine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NATURE-ETN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NATURE-ETN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

ORBITAL (2019)

Ocular Research By Integrated Training And Learning

Read More  

Shape-IT (2019)

Supporting the interaction of Humans and Automated vehicles: Preparing for the EnvIronment of Tomorrow

Read More  

DISTINCT (2019)

Dementia: Intersectorial Strategy for Training and Innovation Network for Current Technology (DISTINCT)

Read More